Form 4: Abbott CFO Sells Shares for Tax Obligations

Abbott Laboratories' EVP and CFO, Philip P. Boudreau, disposed of 387 common shares to cover tax withholding obligations at a price of $132.66 per share.

Summary

• Philip P. Boudreau, Executive Vice President and Chief Financial Officer of Abbott Laboratories, reported a transaction on September 1, 2025.
• The transaction involved the disposition of 387 common shares without par value.
• The shares were disposed of at a price of $132.66 per share.
• This disposition was made to satisfy tax withholding obligations, indicated by transaction code 'F'.
• Following this transaction, Mr. Boudreau directly beneficially owns 50,616 common shares.
• Additionally, 363 shares are indirectly held in the Abbott Laboratories Stock Retirement Trust as of September 1, 2025.
• The transaction was executed pursuant to a Rule 10b5-1(c) plan, indicating a pre-scheduled, non-discretionary sale.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The transaction is routine for tax purposes and executed under a 10b5-1 plan, indicating no discretionary selling based on new information. It's a normal part of executive compensation management.

Positives

• The transaction was a disposition for tax withholding, not a discretionary sale, which is a common practice for executives receiving equity compensation.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-scheduled, non-discretionary sale and mitigating concerns about insider sentiment.

Negatives

• A reduction in direct beneficial ownership by 387 shares, although for tax purposes.

Future Outlook

This filing, a Form 4, does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This is a routine insider transaction for tax purposes, common across industries for executives receiving equity compensation. It does not reflect a change in strategic direction or operational performance for Abbott Laboratories or the broader healthcare industry.

Comparison to Industry Standards

• The disposition of shares to cover tax obligations upon vesting of equity awards is a standard practice for executives across all industries.
• It is not indicative of a lack of confidence in the company, nor does it suggest any deviation from typical corporate compensation and tax management practices observed in peer companies like Johnson & Johnson (JNJ) or Medtronic (MDT).

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine tax-related transaction by an executive, not a discretionary sale indicating a change in sentiment.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary sale of shares by a key executive to cover tax obligations, executed under a pre-arranged 10b5-1 plan. Such transactions are common and do not typically signal a change in the company's fundamentals or the executive's confidence. Therefore, it provides no new information that would warrant a change from a 'hold' recommendation, assuming the investor's existing thesis on Abbott Laboratories remains intact.

Keywords

Abbott Laboratories, ABT, Form 4, Insider Trading, Philip P. Boudreau, CFO, Share Disposition, Tax Withholding, 10b5-1 Plan